Recent Advances Using Anti-CTLA-4 for the Treatment of Melanoma

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Journal

• Publication date

  2009-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/PPO.0b013e3181a7450fPMID 19556898
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I/II trial of tremelimumab in patients with metastatic melanoma.

  2009cited by this paper
• Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade

  2009cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2009cited by this paper
• Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

  2008cited by this paper
• Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine

  2008cited by this paper
• CTLA-4 Control over Foxp3+ Regulatory T Cell Function

  2008cited by this paper
• CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

  2008cited by this paper
• CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

  2008cited by this paper
• CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?

  2008cited by this paper
• Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade

  2008cited by this paper
• The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.

  2008cited by this paper
• Phase I/II study of ipilimumab for patients with metastatic melanoma.

  2008cited by this paper
• Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment

  2008cited by this paper
• Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

  2008cited by this paper
• Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study

  2008cited by this paper
• Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma

  2008cited by this paper
• Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody

  2008cited by this paper
• Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

  2007cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2007cited by this paper
• Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease

  2007cited by this paper
• The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma

  2007cited by this paper
• Reaching first base in the treatment of metastatic melanoma.

  2006cited by this paper
• Response to Comment on “Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade”

  2006cited by this paper
• DURABLE RESPONSES AND LONG-TERM PROGRESSION- FREE SURVIVAL OBSERVED IN A PHASE II STUDY OF MDX- 010 ALONE OR IN COMBINATION WITH DACARBAZINE (DTIC) IN METASTATIC MELANOMA.

  2005cited by this paper
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

  2005cited by this paper
• CTLA4 gene polymorphism and autoimmunity

  2005cited by this paper
• CTLA4 polymorphisms are associated with vitiligo, in patients with concomitant autoimmune diseases.

  2005cited by this paper
• Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

  2005cited by this paper
• Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

  2003cited by this paper

• Immunotherapy research for prostate cancer from 2000 to 2024: a bibliometric and visualization analysis

  2025cites this paper
• Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers

  2024cites this paper
• Strategies to Target Tumor Immunosuppression

  2020cites this paper
• Optimizing the Targeting of Mouse Parvovirus 1 to Murine Melanoma Selects for Recombinant Genomes and Novel Mutations in the Viral Capsid Gene

  2018cites this paper
• Recent advances in applying nanotechnologies for cancer immunotherapy

  2018cites this paper
• Induction of eEF2-specific antitumor CTL responses in vivo by vaccination with eEF2-derived 9mer-peptides.

  2016cites this paper
• Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity

  2014cites this paper
• Chemokines in Cancer Development and Progression and Their Potential as Targeting Molecules for Cancer Treatment

  2014cites this paper
• Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy.

  2013cites this paper
• Tumor‐Targeted Superantigens

  2013cites this paper
• Tumor Immunotherapy by Utilizing a Double-Edged Sword, Chemokines

  2013cites this paper
• Immunomodulatory Therapy of Solid Tumors : With a Focus on Monoclonal Antibodies

  2013cites this paper
• Adoptive T-cell Therapy

  2013cites this paper
• Irradiation of Donor Mononuclear Cells for Treatment of Chemorefractory Metastatic Solid Cancers: A Community-Based Immune Transplant Pilot Study

  2012cites this paper
• Genetic engineering with T cell receptors.

  2012cites this paper
• 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?

  2012cites this paper
• The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma.

  2012cites this paper
• New insights into chronic inflammation-induced immunosuppression.

  2012cites this paper
• Intradermal Immunization

  2012cites this paper
• Rodent Glioma Models: Intracranial Stereotactic Allografts and Xenografts.

  2012cites this paper
• Dissecting the Role of 4-1BB and its Ligand in Enhancing CD8 Effector and Memory T Cell Responses

  2012cites this paper
• eview ew insights into chronic inflammationinduced inflammationinduced inflammationinduced immunosuppression

  2012cites this paper
• Harnessing the Immune System to Fight Cancer: The Promise of Genetic Cancer Vaccines

  2011cites this paper
• CTLA-4 (CD152) blockade does not cause a pro-inflammatory cytokine profile in regulatory T cells.

  2011cites this paper
• Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.

  2011cites this paper
• Current and planned multicenter trials for patients with primary or metastatic melanoma

  2011cites this paper
• Improving cancer immunotherapy by targeting tumor-induced immune suppression

  2011cites this paper
• Differential expression patterns of capping protein, protein phosphatase 1, and casein kinase 1 may serve as diagnostic markers for malignant melanoma

  2011cites this paper
• Caractérisation de DKK1 comme antigène tumoral et manipulation des lymphocytes T CD8 : utilisation de la voie de Wnt en immunothérapie du cancer

  2011cites this paper
• Vaccine Therapy for Melanoma

  2011cites this paper
• Vaccines of the future.

  2011cites this paper
• B7-H4 Expression in Human Melanoma: Its Association with Patients' Survival and Antitumor Immune Response

  2011cites this paper
• Antibodies in oncology.

  2011cites this paper
• Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination

  2011cites this paper
• Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy.

  2011cites this paper
• Vaccines and future global health needs

  2011cites this paper
• Modulation of tumor immunity by therapeutic monoclonal antibodies

  2011cites this paper
• Most common skin tumours in correlation with solar ultraviolet radiation in the area of West Herzegovina.

  2011cites this paper
• Cancer Therapy : Preclinical Local Activation of CD 8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD 40 Antibody

  2011cites this paper
• Treating cancer with genetically engineered T cells.

  2011cites this paper
• Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

  2011cites this paper
• Tumor Evasion from T Cell Surveillance

  2011cites this paper
• Tolerated Oral Agents Preclinical Anti-Tumor Activities as Phosphatase Inhibitor-1 and Analogs with Novel SHP-1 Inhibitors Tyrosine

  2010cites this paper
• RECENT PROGRESS AND FUTURE DIRECTIONS USING ENGINEERED T CELLS FOR THE TREATMENT OF CANCER

  2010cites this paper
• of T Cell Activation and Synapse Formation

  2010cites this paper
• Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis

  2010influential citation
• Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.

  2010cites this paper
• Functional anatomy of T cell activation and synapse formation.

  2010cites this paper
• OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.

  2010cites this paper
• clinical practice guidelines Melanoma : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow-up

  2010cites this paper
• Monoclonal antibodies: versatile platforms for cancer immunotherapy

  2010cites this paper
• Velimogene aliplasmid

  2010cites this paper
• Single dose of anti–CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance

  2010cites this paper
• Gene-expression profiling in vaccine therapy and immunotherapy for cancer

  2010cites this paper
• CTLA4-induced splenomegaly and a review of the literature pertaining to autoimmune complications of therapy.

  2010cites this paper
• Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cites this paper
• Targeting inhibitory pathways in cancer immunotherapy.

  2010cites this paper
• Regulatory T cells in HIV immunotherapy.

  2010cites this paper
• Combining oncolytic virotherapy and tumour vaccination.

  2010cites this paper
• Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses

  2010cites this paper
• Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

  2010cites this paper
• Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression

  2010cites this paper
• Novel SHP-1 Inhibitors Tyrosine Phosphatase Inhibitor-1 and Analogs with Preclinical Anti-Tumor Activities as Tolerated Oral Agents

  2010cites this paper
• Immunity leashed - mechanisms of regulation in the human immune system

  2010cites this paper
• Ipilimumab for advanced melanoma: let's not throw caution to the winds.

  2010cites this paper
• Anti-GBM disease following CTLA4 blockade in a patient with metastatic melanoma

  2010influential citation
• Case Report Anti-GBM disease following CTLA4 blockade in a patient with metastatic melanoma

  2010cites this paper
• Antibodies in cancer immunotherapy

  2009cites this paper